Jennifer Rohn (0000-0001-8766-6056)

Personal information

Biography

I was born in Stow, Ohio USA, received a BA in Biology summa cum laude from Oberlin College in 1990, and a PhD in Microbiology from the University of Washington, Seattle in 1996 studying retroviral pathogen/host interactions in a cat model. I performed post-doctoral research on apoptosis and cancer at the Cancer Research UK London Research Institute in the lab of Prof Gerard Evan FRS, then led a research team at Leadd BV, a start-up biotech company in the Netherlands, discovering novel drug targets for cancer. After a research career break, I won a Wellcome Trust Career-Entry Fellowship at the MRC Laboratory for Molecular Cell Biology at UCL, gaining expertise in high-throughput RNA interference screening to study the role of actin and the cytoskeleton in cell shape and movement. When this was completed, I moved to my current post in 2012, in the Department of Renal Medicine at UCL, where I oversee a basic sciences lab studying the host/pathogen interactions of chronic urinary tract infection in a clinical context. I became the Head of the Centre for Urological Biology in that department in 2018. I became a naturalized British citizen in 2011.

Activities

Collapse all

UCL : London, GB

2007 to present

Employment

Jennifer Rohn

https://orcid.org/0000-0001-8766-6056

Personal information

Websites & social links

Biography

Activities

Employment (5)

UCL : London, GB

Society of Chemical Industry: London, GB

Biomed Central Ltd: London, London, GB

Leadd BV: Leiden, NL

London Research Institute, Cancer Research UK: London, London, GB

Education and qualifications (1)

Oberlin College: Oberlin, OH, US

Works (50 of 53)

Bacterial adhesion strategies and countermeasures in urinary tract infection

3D-UHU-TU: A Three-Dimensional Bladder Cancer Model in a Healthy Urothelial Environment

FuturePub London - International Women's Day

London calling: The 5th UK Cellular Microbiology Network Meeting

A human urothelial microtissue model reveals shared colonization and survival strategies between uropathogens and commensals

Drug delivery strategies for antibiofilm therapy

An immunoresponsive three-dimensional urine-tolerant human urothelial (3D-UHU) model to study urinary tract infection

Severe Acute Respiratory Syndrome Type 2‐Causing Coronavirus: Variants and Preventive Strategies

Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement

The great host‐pathogen war: U.K. Cellular microbiology meeting 2020

The UK cellular microbiology network: Exploring the host‐bacterial interface

Evolution of Communities in the Medical Sciences: Evidence from the Medical Words Network

Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection.

An encapsulated drug delivery system for recalcitrant urinary tract infection.

Discrediting microscopic pyuria and leucocyte esterase as diagnostic surrogates for infection in patients with lower urinary tract symptoms: results from a clinical and laboratory evaluation.

Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms.

Inovio.

Changes in Ect2 localization couple actomyosin-dependent cell shape changes to mitotic progression.

FMNL2 drives actin-based protrusion and migration downstream of Cdc42.

Tensha therapeutics.

Differential regulation of actin microfilaments by human MICAL proteins.

Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration.

Newsmaker: Zafgen.

Comparative RNAi screening identifies a conserved core metazoan actinome by phenotype.

Give postdocs a career, not empty promises.

Women scientists must speak out.

Newsmaker: anaphore.

Tao-1 is a negative regulator of microtubule plus-end growth.

Genzyme partners TJAB.

Actin and cellular architecture at a glance.

Cell shape: taking the heat.

Relevance of apoptin's integrity for its functional behavior.

Underlying molecular mechanisms of tumorigenesis (2)----unbalance between proliferation and cell death

Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen.

Gene targeting: attention to detail.

Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing.

The viral death effector Apoptin reveals tumor-specific processes.

Apoptin's functional N- and C-termini independently bind DNA.

Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion.

Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA.

Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis.

Apoptin induces tumor-specific apoptosis as a globular multimer.

A tumor-specific kinase activity regulates the viral death protein Apoptin.

Akt mediates insulin rescue from apoptosis in brown adipocytes: effect of ceramide.

Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains.

Lymphokines modulate the growth and survival of thymic tumor cells containing a novel feline leukemia virus/Notch2 variant.

The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis.

In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model.

Peer review (4 reviews for 3 publications/grants)